Yair Lotan1, Stephen A Boorjian2, Jingbin Zhang3, Trinity J Bivalacqua4, Sima P Porten5, Thomas Wheeler6, Seth P Lerner6, Ryan Hutchinson7, Franto Francis7, Elai Davicioni3, Robert S Svatek8, Chun-Liang Chen8, Peter C Black9, Ewan A Gibb3. 1. Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: yair.lotan@utsouthwestern.edu. 2. Mayo Clinic, Rochester, MN, USA. 3. GenomeDx Inc, Vancouver, BC, Canada. 4. John Hopkins Medical Institute, Baltimore, MD, USA. 5. University of California San Francisco, San Francisco, CA, USA. 6. Baylor College of Medicine, Houston, TX, USA. 7. Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. 8. University of Texas Health San Antonio, San Antonio, TX, USA. 9. Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, USA.
Abstract
BACKGROUND: Upstaging of clinical T1-T2 urothelial carcinoma (UC) to non-organ-confined (NOC) pathological stage ≥T3 or N+ at radical cystectomy (RC) is common. Tools for stratifying patients who may have NOC disease are limited. OBJECTIVE: To determine an association of a genomic subtyping classifier (GSC) with pathological upstaging in multi-institutional cohort of patients with cT1-T2 UC treated with RC. DESIGN, SETTING, AND PARTICIPANTS: Precystectomy transurethral specimens from 206 patients with high-grade, cT1-T2, N0M0 UC, who underwent RC without neoadjuvant chemotherapy, underwent GSC testing. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Uni- and multivariable logistic regression analyses evaluated GSC for upstaging, defined as pT3/T4 and/or pTanyN1-3 disease at RC. RESULTS AND LIMITATIONS: Pathological upstaging occurred in 23% of cT1 and 57% of cT2 cases. Lower rates of upstaging to NOC was seen for luminal versus nonluminal tumors (34% vs 51%, p=0.02). The differences in upstaging were confined to T stage, with no difference in node positivity for luminal versus nonluminal patients (cT1: 13% for both [p>0.9], cT2: 15% and 23% [p=0.6], respectively). Fewer patients with luminal tumors were upstaged to ≥pT3Nany compared with nonluminal tumors (Mantel-Haenszel p=0.002; cT1: 13% vs 30%, cT2: 34% vs 58%). On multivariable logistic regression analysis, nonluminal patients were more likely to be upstaged to ≥pT3 at RC (p<0.001). Limitations include retrospective design and sample size. CONCLUSIONS: Molecular subtyping of clinically localized UC demonstrated that luminal tumors have lower rates of upstaging to non-organ-confined disease compared with nonluminal tumors. If validated, these data can help inform which patients may need multimodal therapy. PATIENT SUMMARY: Determining whether bladder cancer has spread beyond the bladder is challenging at diagnosis. In this paper, genomics helped identify patients who were more likely to have aggressive disease that has spread outside the bladder. These patients may benefit from chemotherapy prior to surgery.
BACKGROUND: Upstaging of clinical T1-T2 urothelial carcinoma (UC) to non-organ-confined (NOC) pathological stage ≥T3 or N+ at radical cystectomy (RC) is common. Tools for stratifying patients who may have NOC disease are limited. OBJECTIVE: To determine an association of a genomic subtyping classifier (GSC) with pathological upstaging in multi-institutional cohort of patients with cT1-T2 UC treated with RC. DESIGN, SETTING, AND PARTICIPANTS: Precystectomy transurethral specimens from 206 patients with high-grade, cT1-T2, N0M0 UC, who underwent RC without neoadjuvant chemotherapy, underwent GSC testing. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Uni- and multivariable logistic regression analyses evaluated GSC for upstaging, defined as pT3/T4 and/or pTanyN1-3 disease at RC. RESULTS AND LIMITATIONS: Pathological upstaging occurred in 23% of cT1 and 57% of cT2 cases. Lower rates of upstaging to NOC was seen for luminal versus nonluminal tumors (34% vs 51%, p=0.02). The differences in upstaging were confined to T stage, with no difference in node positivity for luminal versus nonluminal patients (cT1: 13% for both [p>0.9], cT2: 15% and 23% [p=0.6], respectively). Fewer patients with luminal tumors were upstaged to ≥pT3Nany compared with nonluminal tumors (Mantel-Haenszel p=0.002; cT1: 13% vs 30%, cT2: 34% vs 58%). On multivariable logistic regression analysis, nonluminal patients were more likely to be upstaged to ≥pT3 at RC (p<0.001). Limitations include retrospective design and sample size. CONCLUSIONS: Molecular subtyping of clinically localized UC demonstrated that luminal tumors have lower rates of upstaging to non-organ-confined disease compared with nonluminal tumors. If validated, these data can help inform which patients may need multimodal therapy. PATIENT SUMMARY: Determining whether bladder cancer has spread beyond the bladder is challenging at diagnosis. In this paper, genomics helped identify patients who were more likely to have aggressive disease that has spread outside the bladder. These patients may benefit from chemotherapy prior to surgery.
Authors: Céline S C Hardy; Hamid Ghaedi; Ava Slotman; Gottfrid Sjödahl; Robert J Gooding; David M Berman; Chelsea L Jackson Journal: J Histochem Cytochem Date: 2022-04-19 Impact factor: 4.137
Authors: Joshua J Meeks; Hikmat Al-Ahmadie; Bishoy M Faltas; John A Taylor; Thomas W Flaig; David J DeGraff; Emil Christensen; Benjamin L Woolbright; David J McConkey; Lars Dyrskjøt Journal: Nat Rev Urol Date: 2020-03-31 Impact factor: 14.432
Authors: Carissa E Chu; Jonathan Chou; Martin Sjöström; Emily A Egusa; Ewan A Gibb; Michelle L Badura; Jun Zhu; Vadim S Koshkin; Bradley A Stohr; Maxwell V Meng; Raj S Pruthi; Terence W Friedlander; Yair Lotan; Peter C Black; Sima P Porten; Felix Y Feng Journal: Clin Cancer Res Date: 2021-06-09 Impact factor: 12.531
Authors: Juan Carlos Pardo; Vicenç Ruiz de Porras; Andrea Plaja; Cristina Carrato; Olatz Etxaniz; Oscar Buisan; Albert Font Journal: Int J Mol Sci Date: 2020-08-29 Impact factor: 5.923